NCT07687576 Comparative Evaluation of Sustained meChanical AsPiration Thrombectomy and no Thrombus Modification for Pre-stent Thrombus bUrden Reduction in Patients With Acute Myocardial Infarction Study: the CAPTURE AMI Study
| NCT ID | NCT07687576 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Oxford University Hospitals NHS Trust |
| Condition | STEMI - ST Elevation Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-07-08 |
| Primary Completion | 2027-07-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 60 participants in total. It began in 2026-07-08 with a primary completion date of 2027-07-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CAPTURE AMI trial is an investigator-initiated, single-centre, two-arm, randomised controlled trial. Patients aged ≥ 18 years who present with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) will be enrolled after angiographic evidence of a high thrombus burden (TIMI thrombus grade ≥ 4) and meeting the inclusion criteria laid out in section 9.2 will be 1:1 randomised to receive either standalone PCI (Arm 1) or adjunct sustained mechanical thrombectomy + PCI (Arm 2). The CAPTURE AMI study will enrol specifically patients with: A. Evidence of high thrombus burden on coronary angiography (TIMI thrombus grade ≥ 4) B. Culprit in an artery with a diameter of 3.0 mm or more. The trial is designed to evaluate the efficacy of sustained mechanical thrombectomy versus standalone PCI in patients with a large thrombus burden assessed angiographically, with a pre-stent thrombus burden (%) as the primary imaging endpoint.
Eligibility Criteria
Inclusion Criteria: * Primary PCI patient with ST elevation myocardial infarction * Angiographic criteria: * TIMI 0/1 flow at presentation * Angiographic thrombus score ≥ 4 * Vessel diameter at site of occlusion ≥ 3.0mm (determined by coronary angiography) Exclusion Criteria: * Female participant who is pregnant or lactating * Unconscious at presentation * Late STEMI presentation (symptoms onset to wire time \> 12 h) * Clinically/haemodynamically unstable patients * Known diagnosis of severe renal disease (CKD stage 4-5) * Suspected spontaneous coronary artery dissection * Previous CABG * Previous history on STEMI in the same culprit territory * Known moderate-severe anaemia (Hb \< 9)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07687576 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying STEMI - ST Elevation Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07687576 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07687576 currently recruiting?
Yes, NCT07687576 is actively recruiting participants. Contact the research team at GiovanniLuigi.DeMaria@ouh.nhs.uk for enrollment information.
Where is the NCT07687576 trial being conducted?
This trial is being conducted at Oxford, United Kingdom.
Who is sponsoring the NCT07687576 clinical trial?
NCT07687576 is sponsored by Oxford University Hospitals NHS Trust. The trial plans to enroll 60 participants.